Skip to main content
. 2017 Mar 31;25(5):1248–1258. doi: 10.1016/j.ymthe.2017.03.010

Table 2.

Patient Characteristics

ID Sex Age (years) Primary Lesion Resectiona Differentiation Metastasis Lesion Numberb Largest Size (cm)c Prior Chemotherapy Other Agents Latest Evaluationd Living Interval (months)e
1 M 61 sigmoid Y median liver >10 13.4 XELOX N PD 14
2 M 37 transverse colon Y median liver, LN 1 4.5 FOLFOX N PD 19
3 M 70 rectum N median liver, lung, LN >10 4.8 XELOX, FOLFOX, XELIRI, bevacizumab CIK stable disease 21
4 M 69 rectum Y low liver, lung, LN >10 8.2 FOLFOX6, FOLFORI radiotherapy PD 21
5 M 68 sigmoid Y median liver, RAG, LN 2 9.2 FOLFOX, FOLFORI, Xeloda radiotherapy PD 22
6 F 51 ileocecumf N median enterocoelia extensive 6.8 FOLFORI, bevacizumab N PD 6
7 M 64 rectum Y median liver, lung >10 2.4 FOLFOX, FOLFORI, XELOX N PD 37
8 F 37 ascending colon Y median vertebra, LN 1 NE FOLFOX, MFOLFOX, XELOX, IRIS, bevacizumab, Xeloda radiotherapy stable disease 16
9 M 48 ascending colon Y median liver, lung, LN >10 10.8 FOLFOX, XELOX, FOLFIRI, SOX CIK, RF PD 77
10 F 55 rectum Y median liver, lung, anastomosis, LN 9 1.9 CAPEOX, Xeloda, bevacizumab radiotherapy, RF PD 32

CIK, cytokine-induced killers; F, female; LN, lymph node; M, male; N, no; NE, lesions on the vertebrae and lymph nodes were not evaluable; RAG, right adrenal gland; RF, radiofrequency ablation on liver lesions; Y, yes.

a

Resection represents primary lesion resection.

b

Lesion numbers do not include primary lesion and lymph node lesions.

c

Largest size is long diameter of the largest metastatic lesion.

d

Living interval is months from the first diagnosis to CAR-T infusion.

e

Latest evaluation before enrollment.

f

Lesionectomy was canceled for P6 because of extensive abdominal metastasis found during surgery.